Durlaza™
Phase 1Small molecule
Durlaza™ is one of 42 small molecule programs targeting Heart Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
166 competitors in Heart Disease
#DrugCompanyPhaseTrials
1Lopid
PfizerPhase 3
Aldactone
PfizerPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Biaxin
AbbViePhase 3
Depo-Provera
Eli LillyPhase 3
Activella
Eli LillyPhase 3
Zoloft
VViatris Specialty LLC
Phase 3
Vivarin
HHikma Pharmaceuticals LLC
Phase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Comparator: Statins
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Durlaza™. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNew Haven Pharmaceuticals, Inc.